Cross Pollinate
A Collaborative Community of Private Investors Learning from each other
Cross Pollinate is a unique community within the family office, family enterprise and private investor landscape. There are no membership fees, no sponsorship and all content is peer generated. Instead of paying dues, or giving their attention to sponsors, community members are expected to contribute questions, experiences and support others in the community for the benefit of all.
Cross Pollinate has been convening gatherings since 2013, with the goal of enriching the community and all its forms of capital. Members of the community contribute their unique perspective and experiences and are open to the contributions and experiences of others.
Contact us if you would like to know more about the community and its members.
Founder
Mark Youngblood
“Cross Pollinate is unique in its prioritization of community and depth of connection.”
Cross Pollinate was created and is led by Mark Youngblood with the advice and support of several family office advisers who are actively involved in the Cross Pollinate Community.
Prior Cross Pollinate, Mr. Youngblood held senior roles in multiple alternative investment firms and a single family office. Mark is a natural community builder who has created and led multiple investment communities including the Seattle and Portland Alternative Investment Associations.
The Cross Pollinate Community was created by, and for, individuals looking for deeper connections with their peers than is available at conferences, networking events and industry organizations. The Cross Pollinate Community is stewarded by thought leaders who have been involved with the family office community for decades.
Qualities
Inclusive, Collaborative, and Meaningful
Contribute
Share questions, experiences and wisdom in a confidential environment
Learn
Gain the knowledge, relationships and experiences of the community
Benefit
Leverage the wisdom, connections and opportunities within your family enterprise
Cross Pollinate Investments
During the 2019 Cross Pollinate Wine Retreat, several attendees discussed a local biotechnology business visited prior to the event. The attendees thought we should collectively invest in this business; leveraging the unique intellectual, human, relational and financial capital of the group. From this discussion, the partnership “Cross Pollinate Absci” was born in June 2020.
Cross Pollinate Capital partnerships have historically aligned interests of investors by charging an interest in profits with minimal fees or expenses.
Cross Pollinate’s initial partnership was dissolved, following the distribution of shares of Absci (NASDAQ: ABSI) following its successful initial public offering in July 2021. Additional partnerships investments were made into the software and bio-manufacturing business listed below.
A generative AI drug creation company on a mission to create better biologics for patients, faster.
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.
Actionable Intel for the Emergency Services Community
Accelerate research with fast and reliable supply of Plasmid DNA
